HSC faculty receives U.S. patent for cancer-fighting therapy

SBS Dr. Porunelloor and Stephen Mathew

When patients are diagnosed with breast or prostate cancer, the treatment course is typically surgery, chemotherapy, hormonal therapy, radiation therapy or a combination of these.

Now, two researchers at the University of North Texas Health Science Center at Fort Worth are working toward a future where patients can be cured in a matter of days with immunotherapy.

Porunelloor Mathew, PhD, Professor, Microbiology, Immunology & Genetics, and Stephen Mathew, PhD, Assistant Professor, Microbiology, Immunology & Genetics, School of Biomedical Sciences, are now one step closer to that goal after recently receiving a U.S. patent for their therapy, “Compositions and methods for activation of NK cells killing of prostate and breast cancer cells.”

The two have been working together on cancer research for the last 20 years, with specific interest in the body’s natural killer, or “NK” cells, and harnessing their potential to cure certain cancers.

“We want to focus now on breast and prostate cancers,” said Dr. Porunelloor Mathew. “They are some of the most common cancers among women and men, respectively, so we have the biggest chance to make a significant impact.”

“In the traditional treatments for these cancers, while most of the cancer cells are killed, there is damage to the healthy cells as well,” he explained. “But when the cancer cells escape from traditional treatments, there is opportunity for the disease to return or metastasize to other parts of the body.”

“The advantage to immunotherapy with NK cells is that they seek out and kill all of the cancer cells, even those that are hidden, so the cancer cannot continue to grow.”

With the patent awarded, the next step for the doctors is to develop this immunotherapy to be compatible for use in humans and take it to clinical trials within the next three to four years.

“If it works, we’ve seen the Food and Drug Administration (FDA) fast-track the approval process,” said Dr. Stephen Mathew. “Our previous discovery has been similarly approved by FDA in the treatment of multiple myeloma, another type of cancer, and the success rates have been significant.”

“There is great potential for harnessing NK cells to cure different cancers. With immunotherapy, we are not using harsh chemicals. We’re making it possible for the body to boost its own immune system,” he added. “Ultimately, nature has its own way of curing — we are just creating a pathway for nature to take its course.”

Recent News

Stephanie Ibekwe
  • Our People
|Dec 5, 2022

A voice for women in medicine

When Dr. Stephanie Ibekwe’s mother, Sarah, came home from her nursing job, she would tell her daughter stories about her patients and the conversations she had with them. “Nursing is pretty stressful, but my mom had an amazing way of handling things,” she said. “My mom really loved to bui...
Noah Peeri Headshot
  • Our People
|Dec 5, 2022

SPH alum Dr. Noah Peeri produces JAMA Oncology publication just months after graduation

Noah Peeri, Ph.D., MPH, a recent graduate of The University of North Texas Health Science Center’s School of Public Health, has achieved a major milestone by publishing an article in the Journal of the American Medical Association Oncology just months after completing his graduate degree.   H...
Techstars Demo Day.
  • On Campus
|Dec 1, 2022

Techstars Demo Day brings innovation to the historic stockyards

For the last 13 weeks, the founders of 10 of the world’s most innovative startups have been in Fort Worth perfecting their new physical health technology. They are part of the world’s first physical health accelerator, and now they are ready to show the fruits of their labor. Techstars Demo D...
Dr. Sid O'bryant Award
  • Our People
|Dec 1, 2022

HSC named the winner of the D Magazines 2022 Achievement in Medical Research Award

The extensive research done by Dr. Sid O’Bryant and his team at the Institute of Translational Research has earned the University of North Texas Health Science Center at Fort Worth the 2022 Medical Research Award by D Magazine. Dr. O’Bryant, the executive director of the ITR and a professor at t...